#China #Suzhou #Insilico Medicine #Ribo Life Science #siRNA drug

Ribo and Insilico Medicine: A Revolutionary Collaboration in Drug Development

Suzhou Ribo Life Science Co., Ltd. (traded as 06938.HK) has recently announced a strategic partnership with Insilico Medicine (03696.HK) aimed at accelerating the development of innovative drugs based on small interfering RNA (siRNA). This collaboration marks a significant milestone in leveraging artificial intelligence (AI) in the pharmaceutical development process, underscoring both companies' commitment to addressing unmet clinical needs.

The world of medicine is evolving with the ongoing integration of technology, particularly AI, into drug discovery and development. With this alliance, Ribo and Insilico will combine their strengths: Ribo's expertise in siRNA drug development and Insilico's prowess in AI-driven drug discovery. This collaboration will delve into target discovery, molecular design, optimization, and clinical translation, taking full advantage of both companies' capabilities.

siRNA-based drugs have become crucial in modern medicine due to their ability to silence pathogenic genes precisely. This targeted approach allows for a broad range of applications, along with reduced development cycles and improved patient adherence through prolonged therapeutic effects. The incorporation of advanced AI technology is expected to enhance the efficiency and success rates of developing siRNA drugs, particularly for targets that are challenging to treat with conventional methods.

Ribo is already utilizing AI within its drug development framework, having established a sophisticated platform for efficiently designing siRNA sequences and high-throughput ligand screening. These technological advancements enable rapid identification, iteration, and optimization of candidate molecules, significantly improving clinical development success. In previous collaborations, including intelligent autonomous screening, Ribo and Insilico have demonstrated promising results, paving the way for this more robust partnership.

According to Feng Ren, co-CEO and Chief Scientific Officer of Insilico Medicine, “We are excited to formalize this cooperation with Ribo. Our two companies have fostered a strong relationship built on mutual trust and collaboration. Ribo's participation in our automated lab platform, LifeStar 2, serves as a key example of the effectiveness of our cooperative ventures.” He further highlighted the enhancements brought about by Insilico’s Pharma.AI platform, emphasizing the companies' shared vision of exploring groundbreaking drug development scenarios.

Ribo’s commitment to innovation aligns perfectly with Insilico's mission, as articulated by Li-Ming Gan, co-CEO and global head of R&D at Ribo. He stated, “We are entering a new era of clinical research and development guided by AI. Our previous fruitful collaboration has evolved into a comprehensive strategic partnership. Ribo is now in an accelerated development phase, producing a large number of candidate drugs and executing clinical trials effectively. We aim to leverage Insilico’s Pharma.AI platform to enhance our strategic development initiatives.”

This partnership holds the potential not only to revolutionize drug development processes but also to deliver innovative therapeutic solutions tailored for the evolving healthcare landscape. Through this continued collaboration, both companies hope to respond to the persistent challenges in healthcare, ensuring more effective, targeted treatments enter the market sooner than ever.

About Insilico Medicine

Insilico Medicine is a global leader in biotechnology that combines AI and automation technologies to expedite drug discovery efforts, ultimately aiming to enhance human health and longevity. Following its listing on the Hong Kong Stock Exchange on December 30, 2025, under code 03696.HK, Insilico continues to push the boundaries of drug development through its proprietary Pharma.AI platform.

The company focuses on developing innovative treatments to meet therapeutic needs in various fields including oncology, fibrosis, and metabolic disorders while also extending its applications across sectors like agriculture and veterinary medicine.

About Ribo Life Science

Suzhou Ribo Life Science Co., Ltd. is dedicated to creating siRNA-based therapies and has robustly established its portfolio to target vital pathologies. Building on its siRNA technology platform, Ribo strives to provide groundbreaking therapeutic solutions globally. Following its successful IPO on January 9, 2026, under the Hong Kong Stock Exchange code 06938.HK, Ribo is committed to continuous innovation in improving patient care worldwide.

This collaboration signifies a transformative shift in the pharmaceutical industry, showcasing the crucial intersection of technology and healthcare in creating a brighter future for patients around the globe.